AI assistant
NovoCure Ltd — Director's Dealing 2023
Mar 6, 2023
31949_dirs_2023-03-06_6856612f-eda0-4d46-9d54-a0b85a3b4595.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2023-03-02
Reporting Person: Leonard Frank X (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-03-02 | Ordinary Shares | S | 844.00 | $75.2779 | Disposed | 58144.00 | Direct |
| 2023-03-03 | Ordinary Shares | A | 11808.00 | $0.00 | Acquired | 69952.00 | Direct |
| 2023-03-03 | Ordinary Shares | S | 2059.00 | $77.6391 | Disposed | 67893.00 | Direct |
Footnotes
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Represents vesting of performance-based restricted stock units.
F3: Sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.